ADMS Adamas Pharmaceuticals, Inc. Stock Quote

ADMS [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.03	Insider Own	2.60%	Shs Outstand	28.62M	Perf Week	-7.02%
Market Cap	245.71M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	-0.71%	Shs Float	27.75M	Perf Month	9.92%
Income	-57.40M	PEG	-	EPS next Q	-0.51	Inst Own	53.70%	Short Float	8.63%	Perf Quarter	0.18%
Sales	74.50M	P/S	3.30	EPS this Y	46.60%	Inst Trans	16.23%	Short Ratio	4.38	Perf Half Y	59.71%
Book/sh	-1.75	P/B	-	EPS next Y	48.70%	ROA	-43.30%	Target Price	9.07	Perf Year	64.05%
Cash/sh	1.84	P/C	2.95	EPS next 5Y	-	ROE	183.90%	52W Range	2.43 - 9.15	Perf YTD	25.40%
Dividend	-	P/FCF	-	EPS past 5Y	6.60%	ROI	-	52W High	-40.66%	Beta	2.70
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	107.90%	Gross Margin	97.30%	52W Low	123.46%	ATR	0.35
Employees	138	Current Ratio	3.20	Sales Q/Q	28.80%	Oper. Margin	-59.30%	RSI (14)	51.76	Volatility	7.24% 6.82%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	22.80%	Profit Margin	-77.10%	Rel Volume	0.54	Prev Close	5.43
Shortable	Yes	LT Debt/Eq	-	Earnings	May 10 AMC	Payout	-	Avg Volume	546.76K	Price	5.43
Recom	2.20	SMA20	3.49%	SMA50	5.63%	SMA200	16.95%	Volume	293,158	Change	0.00%

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$10 → $12

Dec-18-19

Reiterated

H.C. Wainwright

Buy

$30 → $10

Sep-30-19

Downgrade

BofA/Merrill

Neutral → Underperform

$9 → $5

Sep-09-19

Initiated

Cantor Fitzgerald

Neutral

Mar-05-19

Downgrade

Mizuho

Neutral → Underperform

$11 → $5

Nov-05-18

Downgrade

Mizuho

Buy → Neutral

Oct-05-18

Downgrade

BofA/Merrill

Buy → Neutral

Jul-16-18

Initiated

H.C. Wainwright

Buy

$45

Apr-04-18

Initiated

Leerink Partners

Outperform

$31

Mar-27-18

Initiated

BofA/Merrill

Buy

$39

Nov-29-17

Initiated

Northland Capital

Outperform

$70

Nov-08-17

Reiterated

Noble Financial

Buy

$33 → $48

Oct-30-17

Initiated

Evercore ISI

Outperform

$85

Sep-29-17

Resumed

Noble Financial

Buy

$33

Sep-19-17

Reiterated

Mizuho

Buy

$26 → $48

Aug-25-17

Reiterated

JMP Securities

Mkt Outperform

$29 → $33

Sep-08-16

Reiterated

Mizuho

Buy

$22 → $26

Jun-17-16

Initiated

Noble Financial

Buy

$25

Jun-16-16

Upgrade

Mizuho

Neutral → Buy

$22

May-12-16

Reiterated

Mizuho

Neutral

$17 → $16

May-03-21 03:01PM	Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-29-21 04:04PM	Adamas to Present at Upcoming BofA Conference Business Wire
Apr-27-21 09:15AM	Adamas Launches "Picture More Time" Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinsons Disease and Care Partners Business Wire
Apr-26-21 04:04PM	Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021 Business Wire +7.34%
Apr-19-21 09:15AM	Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinsons disease presented at American Academy of Neurology (AAN) Annual Meeting Business Wire
Apr-15-21 09:15AM	Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting Business Wire
Apr-07-21 05:19PM	Adamas to Present at Upcoming Needham Conference Business Wire -5.47%
Apr-06-21 01:45AM	What Type Of Shareholders Make Up Adamas Pharmaceuticals, Inc.'s (NASDAQ:ADMS) Share Registry? Simply Wall St.
Mar-29-21 03:12PM	Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows Benzinga -5.27%
09:15AM	Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinsons disease Business Wire
Mar-05-21 04:02PM	Adamas Announces New Employment Inducement Grant Business Wire
Mar-02-21 06:06AM	Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength? Zacks
Mar-01-21 04:04PM	Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire +5.89%
Feb-24-21 09:16PM	Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering Business Wire -7.98%
04:08PM	Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering Business Wire
Feb-23-21 04:44PM	Adamas Pharmaceuticals: Q4 Earnings Insights Benzinga -9.35%
04:03PM	Adamas Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
02:30PM	Adamas Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga
Feb-22-21 10:27AM	A Preview Of Adamas Pharmaceuticals's Earnings Benzinga
Feb-17-21 04:06PM	Adamas to Present at Upcoming Healthcare Conferences Business Wire
Feb-10-21 09:24AM	Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021 Business Wire
Feb-02-21 08:05AM	The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga -15.91%
Feb-01-21 02:07PM	Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinsons Disease Patients Experiencing OFF Episodes Business Wire +14.89%
08:01AM	Adamas Announces Settlement of Patent Litigation with Zydus Business Wire
Jan-13-21 09:15AM	Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021 GlobeNewswire
Jan-07-21 06:02PM	Adamas to Present at Upcoming ICR Conference GlobeNewswire
Jan-05-21 11:59PM	Would Shareholders Who Purchased Adamas Pharmaceuticals' (NASDAQ:ADMS) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
09:15AM	Adamas Completes Acquisition of OSMOLEX ER® GlobeNewswire
Jan-04-21 04:15PM	Adamas to Present at Upcoming H.C. Wainwright Conference GlobeNewswire
Dec-11-20 10:00PM	Is ADMS A Good Stock To Buy Now? Insider Monkey
04:02PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Dec-02-20 06:51AM	Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners GlobeNewswire +8.16%
06:50AM	Adamas Announces Agreement to Settle Patent Litigation with Osmotica GlobeNewswire
Nov-24-20 04:03PM	Adamas to Present at Upcoming Evercore ISI Conference GlobeNewswire
Nov-23-20 09:15AM	Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg GlobeNewswire
Nov-18-20 04:02PM	Adamas to Present at Upcoming Piper Sandler Conference GlobeNewswire
Nov-13-20 04:05PM	Adamas Announces New Employment Inducement Grant GlobeNewswire +5.85%
Nov-07-20 07:12AM	Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Nov-05-20 07:20PM	Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Misses Revenue Estimates Zacks +7.43%
04:03PM	Adamas Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-02-20 09:25AM	Adamas announces settlement agreement of previously disclosed class action litigation GlobeNewswire +11.84%
Oct-29-20 12:35PM	Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-26-20 04:04PM	Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020 GlobeNewswire
Oct-09-20 04:03PM	Adamas Announces New Employment Inducement Grant GlobeNewswire +7.83%
Oct-01-20 09:15AM	Adamas appoints new Chief Medical Officer, Adrian Quartel, MD GlobeNewswire
Sep-11-20 04:04PM	Adamas Announces New Employment Inducement Grant GlobeNewswire -15.02%
09:15AM	Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinsons disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress GlobeNewswire
Sep-08-20 04:05PM	Adamas to Present at Upcoming HC Wainwright Conference GlobeNewswire
Sep-01-20 09:15AM	Adamas Appoints Anna Richo to Board of Directors GlobeNewswire
Aug-21-20 08:51AM	What Kind Of Shareholders Own Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? Simply Wall St. -7.39%
Aug-14-20 04:04PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-11-20 08:06PM	Is Adamas Stock Still Worth Buying After Its 77% Rally? This 5-Star Analyst Says Yes TipRanks -7.83%
Aug-06-20 04:02PM	Adamas Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-30-20 12:33PM	Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-23-20 04:02PM	Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020 GlobeNewswire
Jul-15-20 08:00AM	Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinsons disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform GlobeNewswire
Jul-10-20 04:05PM	Adamas Announces New Employment Inducement Grant GlobeNewswire +6.32%
Jun-18-20 08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga -6.99%
Jun-17-20 04:01PM	Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment GlobeNewswire
Jun-05-20 07:34AM	The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid Benzinga +12.88%
Jun-04-20 04:30PM	Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinsons disease patients receiving levodopa and experiencing OFF episodes GlobeNewswire
Jun-03-20 04:01PM	Adamas to Present at Upcoming William Blair Conference GlobeNewswire
May-20-20 10:04PM	Edited Transcript of ADMS earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-13-20 09:15AM	Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinsons disease - expands coverage with reduction of OFF time and increased good ON time GlobeNewswire -7.48%
May-08-20 06:46PM	Adamas Announces New Employment Inducement Grant GlobeNewswire -13.29%
May-07-20 04:03PM	Adamas Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-30-20 12:34PM	Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks -5.00%
Apr-28-20 12:00PM	All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy Zacks
Apr-27-20 04:03PM	Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 GlobeNewswire
Apr-10-20 04:06PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Mar-23-20 03:15PM	Adamas Pharmaceuticals Stock Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C. GlobeNewswire +7.05%
Mar-20-20 10:44AM	Generic Drugs Industry's Prospects Uncertain Amid Coronavirus Zacks
Mar-19-20 04:46PM	Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C. PR Newswire +21.61%
Mar-10-20 02:26PM	Edited Transcript of ADMS earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-06-20 04:39PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-28-20 06:26AM	Earnings Update: Here's Why Analysts Just Lifted Their Adamas Pharmaceuticals, Inc. Price Target To US$12.69 Simply Wall St.
Feb-25-20 05:35PM	Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.14%
04:03PM	Adamas Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-24-20 09:02AM	Cronos (CRON) to Report Q4 Earnings: What's in the Cards? Zacks -9.33%
Feb-20-20 04:01PM	Adamas to Present at Upcoming Healthcare Conferences GlobeNewswire
Feb-19-20 04:02PM	Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020 GlobeNewswire
Feb-13-20 09:00AM	Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinsons Disease and Movement Disorders Congress GlobeNewswire
Feb-12-20 09:18AM	The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga +6.15%
Feb-11-20 04:15PM	Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinsons Disease GlobeNewswire
Feb-10-20 10:50AM	SHAREHOLDER ALERT: ADMS GDOT BYND: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:00AM	ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
09:57AM	FINAL DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 ACCESSWIRE
Feb-09-20 10:25AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, OPRA and PTLA ACCESSWIRE
Feb-08-20 10:30AM	ADMS FINAL DEADLINE: ROSEN, INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10 Deadline in Securities Class Action - ADMS ACCESSWIRE
Feb-07-20 01:30PM	CLASS ACTION UPDATE for ADMS, GDOT and PTLA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:00AM	DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 GlobeNewswire
Feb-06-20 05:40PM	CLASS ACTION UPDATE for ADMS, SSL and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
01:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
Feb-05-20 06:00PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, GDOT and FSCT ACCESSWIRE
03:15PM	5-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, XYF and PTLA ACCESSWIRE
11:26AM	ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.s January 24, 2018 Secondary Public Offering To Contact The Firm GlobeNewswire
10:52AM	CLASS ACTION UPDATE for ADMS, FSCT and BYND: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:56AM	DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 ACCESSWIRE

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shreedhar Vijay	Chief Commercial Officer	Mar 22	Sale	5.50	1,051	5,780	169,435	Mar 23 06:06 PM
Prentiss Christopher B	Chief Financial Officer	Mar 22	Sale	5.48	2,422	13,273	145,017	Mar 23 06:02 PM
MAHONEY DAVID L	Director	Mar 12	Option Exercise	0.67	48,000	31,920	110,153	Mar 16 05:23 PM
MacPhee John A	Director	Mar 12	Option Exercise	0.67	192,000	127,680	197,000	Mar 16 05:20 PM
Papapetropoulos Spyridon	Director	Mar 11	Buy	5.06	5,975	30,233	15,975	Mar 15 03:24 PM
Prentiss Christopher B	Chief Financial Officer	Feb 01	Sale	6.36	3,821	24,302	72,439	Feb 01 09:39 PM
Shreedhar Vijay	Chief Commercial Officer	Feb 01	Sale	6.39	4,514	28,844	95,486	Feb 01 09:37 PM
Prentiss Christopher B	Chief Financial Officer	Jan 20	Sale	4.41	2,630	11,598	76,260	Jan 22 05:29 PM
Prentiss Christopher B	Chief Financial Officer	Nov 02	Sale	3.21	2,050	6,580	78,890	Nov 02 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience